solriamfetol   Click here for help

GtoPdb Ligand ID: 10342

Synonyms: ADX-N05 | ADXN05 | JZP-110 | JZP110 | Sunosi®
Approved drug
solriamfetol is an approved drug (FDA (2019), EMA (2020))
Compound class: Synthetic organic
Comment: Solriamfetol is a norepinephrine-dopamine reuptake inhibitor that was developed by Jazz Pharmaceuticals [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 78.34
Molecular weight 194.11
XLogP 0.49
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NC(Cc1ccccc1)COC(=O)N
Isomeric SMILES N[C@H](Cc1ccccc1)COC(=O)N
InChI InChI=1S/C10H14N2O2/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H2,12,13)/t9-/m1/s1
InChI Key UCTRAOBQFUDCSR-SECBINFHSA-N
References
1. Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A. (2018)
Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor.
J Pharmacol Exp Ther, 366 (2): 367-376. [PMID:29891587]
2. Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, Chen D, Carter LP, Wang H, Lu Y et al.. (2019)
A randomized study of solriamfetol for excessive sleepiness in narcolepsy.
Ann Neurol, 85 (3): 359-370. [PMID:30694576]